HealthQuiet 17d · day 22
NYU study links GLP-1 weight loss drugs to 7% added hair loss risk in genetically vulnerable men
A genetic study finds men with high GLP1R gene activity who use Ozempic, Wegovy, or Zepbound face elevated risk of male pattern baldness.
What to know
- A NYU Langone study published September 3, 2026 provides the first genetic evidence linking GLP-1 drugs (Ozempic, Wegovy, Zepbound) to increased male pattern baldness risk—7% additional risk for men genetically predisposed.
- The study focused on the GLP1R gene and found its higher activity correlates with both GLP-1 medication use and androgenetic alopecia, suggesting a biological rather than coincidental link.
- Previous hair loss reports among GLP-1 users were attributed to physical stress from rapid weight loss, which is often reversible; this study suggests some genetic vulnerability may increase permanent hair loss risk.
- The research only examined men due to better understanding of male hair loss genetics; findings do not yet extend to women using these drugs.
“Many GLP-1 users, both men and women, have reported thinning hair as a side effect, with researchers so far attributing the shedding to the rapid weight loss driven by the medications”
Study researchers, Research team · NYU Langone Health / PR Newswire ↗ · Sep 2
NYU Langone Health Research institutionLynn Petukhova, PhD Study senior investigator, assistant professor in dermatology
The record 31 articles and posts · last 23 days
- summary covers to here · Sep 4, 2:25 AM · 16 pieces above arrived after